# Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Canonical URL: https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-fourth-quarter-and-full-year-2025-financial-results-on-b86cdf96
Ticker: KRYS
Company: Krystal Biotech
Source: Krystal Biotech
Published: 2026-02-10 13:00 EST
## Summary

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter...

## Article Body
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53598 .

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com .

About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® , the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@krystalbio.com
## Recent Company News
- 2026-07-23 21:00 EST — [Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902) — Source: Krystal Biotech
- 2026-05-18 12:00 EST — [Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatm-23d2eafe) — Source: Krystal Biotech
- 2026-05-07 12:00 EST — [Krystal Biotech to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2026-health-care-conference-f4e6ec6b) — Source: Krystal Biotech
- 2026-05-04 11:00 EST — [Krystal Biotech Announces First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-first-quarter-2026-financial-and-operating-results-9aa0ae94) — Source: Krystal Biotech
- 2026-04-30 12:00 EST — [Krystal Biotech to Present at Upcoming Scientific Conferences](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-upcoming-scientific-conferences-5a0d2417) — Source: Krystal Biotech
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)